Utama › Kanser Pankreas › North Carolina › Durham
Kajian klinikal Kanser Pankreas di Durham, NC
24 kajian untuk Kanser Pankreas sedang mencari peserta di lokasi dalam dan sekitar Durham (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
The Vanguard Study: Testing a New Way to Screen for Cancer
Mengambil pesertaSukarelawan sihat dialu-alukan
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
A Study of PHN-012 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1
- PHN-012-001 Site, Durham
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Mengambil pesertaFasa 3
- Duke Cancer Center, Durham
DESTINY-PANTUMOUR04
Mengambil pesertaKajian pemerhatian
- Research Site, Durham
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Mengambil pesertaFasa 2/3
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauh
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi jauh
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Mengambil pesertaFasa 3
- Duke Cancer Center, Durham
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Mengambil pesertaFasa 3
- Investigative Site US035, Chapel Hill · 10 mi jauh
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Mengambil pesertaFasa 1/2
- Duke University Medical Center, Durham
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Mengambil pesertaFasa 2
- Local Institution - 0100, Durham
Promoting CT Engagement for Pancreatic Cancer With App
Mengambil peserta
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Mengambil pesertaKajian pemerhatian
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
- University of North Carolina-Hillsborough Campus, Hillsborough · 13 mi jauh
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Mengambil pesertaFasa 2
- University of North Carolina, Chapel Hill · 10 mi jauh
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Mengambil pesertaFasa 1
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill · 10 mi jauh
- University of North Carolina, Chapel Hill · 10 mi jauh
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Mengambil pesertaFasa 3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Mengambil pesertaFasa 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
Mengambil pesertaFasa 2
- Duke University Medical Center, Durham
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Mengambil pesertaFasa 1
- Duke Cancer Institute /ID# 276267, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Mengambil pesertaFasa 1
- Research Site, Durham
Autologous CAR-T Cells Targeting B7-H3 in PDAC
Mengambil pesertaFasa 1
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Mengambil pesertaFasa 1
- Duke Cancer Center, Durham
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Mengambil pesertaFasa 1/2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
Mengambil pesertaFasa 2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi jauh
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Mengambil pesertaFasa 2
- University of North Carolina, Chapel Hill · 10 mi jauh
Kajian Kanser Pankreas di bandar lain
- Houston, TX61 kajian
- New York City, NY60 kajian
- Boston, MA43 kajian
- Nashville, TN39 kajian
- Los Angeles, CA35 kajian
- St. Louis, MO33 kajian
- Arlington, VA33 kajian
- Baltimore, MD31 kajian
- San Antonio, TX31 kajian
- Philadelphia, PA26 kajian
- Tampa, FL26 kajian
- San Diego, CA24 kajian
Kajian lain di Durham
- Kanser Payudara64 kajian
- Kanser (semua jenis)58 kajian
- Kanser Paru-paru Bukan Sel Kecil39 kajian
- Mieloma Pelbagai37 kajian
- Leukemia Mieloid Akut33 kajian
- Kanser Metastatik33 kajian
- Kanser Prostat32 kajian
- Kanser Paru-paru32 kajian
- Kanser Kolorektal28 kajian
- Kanser Ovari27 kajian
- Leukemia Limfositik Kronik27 kajian
- Kegagalan Jantung26 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.